Recent Updates
Recently added Catalysts
JNJ

Johnson & Johnson to Participate in the Raymond James 43rd Annual Institutional Investors Conference Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 43rd Annual Institutional Investors Conference on Tuesday, March 8th. Joseph J....

Key Takeaway: NEW BRUNSWICK, N.J. , Feb. 9, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Raymond James 43rd Annual Institutional Investors Conference on Tuesday, March 8 th . Joseph J. Wolk, Executive Vice President and Chief Financial Officer, will represent the
Price reaction · baseline $171.51 (2022-02-08 close) · hit after-hours · clean, no other JNJ news in the window
day 0 close
0%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.6%
average across 15 past catalysts
Lead asset
Canagliflozin
Phase 3 · Diabetes Mellitus, Type 2

Full Press Release Details

NEW BRUNSWICK, N.J. , Feb. 9, 2022 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) will participate in the Raymond James 43rd Annual Institutional Investors Conference on Tuesday, March 8 th . Joseph J. Wolk, Executive Vice President and Chief Financial Officer, will represent the Company in a session scheduled at 1:05 p.m. (Eastern Time) .
This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .
A webcast replay will be available approximately 48-hrs after the live webcast.
Last updated: Feb 9, 2022